Wall Street has been paying a lot of attention to the stock, thanks to the impressive clinical performance ... Preclinical ...

Why is iHeartMedia's stock soaring despite mixed earnings results? The headline numbers don't tell the whole story.

Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS ...

driven by its heart assist devices portfolio, which offers treatment for chronic and temporary conditions. We anticipate the market sentiment toward the stock to remain positive surrounding this ...

iHeartMedia's stock temporarily surged more than 60% following a significant debt restructuring. The third-quarter earnings report was more of a sideshow than a market-moving event. Regrettably ...

The broadcast radio and audio-streaming company's stock cooled down later in the day, but the single-day gain was a robust 24.1% just before 2 p.m. ET. The heart of iHeartMedia's Q3 report was ...